Antibiotics, Dosing, and CFTR
Airway infections are a hallmark of cystic fibrosis, making antibiotic therapies a mainstay of CF treatment. While the fight against ABX resistance is ongoing, newer data are showing that commonly used dosing regimens may have to be altered to account for the particular pharmacodynamics in people with CF. How should ABX dosing be altered, and what additional effect might CFTR modulation have on dosing decisions? That’s the topic Dr. Andrea Hahn, Assistant Professor of Pediatrics and an Infectious Disease Specialist at Children’s National Medical Center and George Washington University School of Medicine and Health Sciences, addresses in this eCysticFibrosis Review podcast. Take our post-test to claim CME credits. To read a companion newsletter click here.
Embed this episode
No transcript yet.